Micrographia Bio

Using machine learning to turn spatial proteomics into a drug discovery engine

First Investment: 2022

If it were possible to watch drugs molecules at work under a microscope — seeing precisely how they act on different proteins inside cells — it would revolutionize drug development. Micrographia is doing just that. The company uses machine learning to analyze microscopy images at high throughput, allowing researchers and drug developers to unravel disease mechanisms at the subcellular level.

News & Insights

Deep Tech Opportunities Report

Deep Tech Opportunity: TechBio companies are using data to rethink how we develop new medical treatments

Explore Companies

Newleos Therapeutics

Transforming the treatment of anxiety and other neuropsychiatric disorders

Grove Biopharma

Putting protein-like drugs inside cells to fight cancer and neurodegeneration

Syntax Bio

Programming stem cells to differentiate into desired cell types, faster

Fable Therapeutics

Using state-of-the-art machine learning models to create custom-build protein drugs